Composition for reducing uric acid and application and product thereof

Through the composition of whole milk powder, oligomeric fructose, resistant dextrin, cranberry juice powder and complex probiotic powder, the intestinal flora is regulated, and the problem of side effects of hyperuricemia drugs is solved, and the problem of toxicity and side effects of hyperuricemia drugs is achieved without The effect of reducing uric acid by side effects is suitable for food and health products.

CN118923728AInactive Publication Date: 2024-11-12ZHEJIANG HENGMEI HEALTH TECH CO LTD

Patent Information

Application Number
CN202411414606.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing drugs for treating hyperuricemia have toxic side effects and lack functional foods without side effects to prevent or reduce uric acid levels.

Method used

Provided is a composition that reduces uric acid, including whole milk powder, fructose oligosaccharide, resistant dextrin, cranberry juice powder and complex probiotic powder, which reduces uric acid by regulating intestinal flora and promoting the growth of beneficial bacteria. and xanthine oxidase levels.

Benefits of technology

It significantly reduces the levels of uric acid and xanthine oxidase, provides uric acid-lowering foods without side effects and palatability, enhances immune function and controls purine production, and is suitable for the prevention and treatment of hyperuricemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118923728A_ABST
    Figure CN118923728A_ABST
Patent Text Reader

Abstract

The invention provides a composition for reducing uric acid as well as application and a product thereof, and belongs to the technical field of foods. The composition for reducing uric acid comprises the following components in parts by weight: 20-35 parts of whole milk powder, 10-30 parts of prebiotics, 8-18 parts of fruit powder and 3-6 parts of compound probiotic powder, the compound probiotic powder is prepared from lactobacillus plantarum TSP05, lactobacillus fermentum TSF331, lactobacillus reuteri TSR332 and maltodextrin, and the compound probiotic powder is prepared from lactobacillus plantarum TSP05, lactobacillus fermentum TSF331 and lactobacillus reuteri TSR332. The composition is clean in formula, green, safe, free of pigment and preservative, free of side effects and good in palatability. The preparation process is simple and reasonable, feasible to operate and high in applicability. The composition provided by the invention can significantly reduce the levels of uric acid and xanthine oxidase, and provides a wide application prospect for preparation of uric acid-reducing products, especially food.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of food technology, and in particular to a composition for reducing uric acid and an application and product thereof. Background Art

[0002] The cells in the human body undergo metabolism every day, and the nucleic acids in the body are broken down to produce purines. These purines produced in the body and the purines ingested from external foods are decomposed by xanthine oxidase and adenosine deaminase in the body, eventually forming uric acid.

[0003] Hyperuricemia is a metabolic disease caused by excessive purine deposition in the body, which results in an increase in uric acid in the blood. Long-term high blood uric acid levels will have a series of adverse consequences on blood vessels, heart, and kidneys, increasing the risk of cancer, hypertension, diabetes, cardiovascular and cerebrovascular diseases, and a high probability of urate deposition in the body, causing gout, which is extremely painful. Due to changes in diet and lifestyle, the number of patients with hyperuricemia and gout has also increased, and it has become a common systemic rheumatic disease in modern society.

[0004] For patients with hyperuricemia, drugs are often used clinically to control blood uric acid levels. Representative drugs include allopurinol, benzbromarone, and lesinad. Although these drugs have clear effects and are quick to take effect, patients with hyperuricemia need to take uric acid-lowering drugs for a long time, and the side effects of drugs in terms of liver and kidney toxicity are not suitable for long-term use. The drugs have strong toxic side effects and low patient tolerance. Dietary intervention may become an effective means of treating hyperuricemia, and while maintaining a normal dietary structure, there are very few functional foods that can effectively prevent the occurrence of hyperuricemia without any side effects. Therefore, there is a great need for suitable daily health foods to reduce the uric acid content in the body.

[0005] Probiotics contain urate oxidase, which can metabolize uric acid into allantoin, which is water-soluble and non-toxic to the human body. It has been proven to have a preventive or therapeutic effect on hyperuricemia. At the same time, probiotics can degrade uric acid and purine nucleosides, or significantly reduce the levels of guanosine and inosine. They can colonize in the intestines to reduce the intestinal absorption of uric acid and purine nucleosides, thereby effectively maintaining the stability of uric acid.

[0006] In summary, therapeutic drugs that inhibit uric acid have very serious toxic side effects. At present, it is necessary to develop a new type of probiotic food to improve uric acid levels through diet therapy. Edible foods that lower blood pressure or uric acid are urgently needed to enter the market. Summary of the invention

[0007] In order to solve the above problems, the present invention provides a composition for reducing uric acid and its application and product. The composition for reducing uric acid comprises, by weight: 20-35 parts of whole milk powder, 10-30 parts of prebiotics, 8-18 parts of fruit powder and 3-6 parts of composite probiotic powder; the composite probiotic powder is composed of Lactobacillus plantarum TSP05, Lactobacillus fermentation TSF331, Lactobacillus reuteri TSR332 and maltodextrin. The composition provided by the present invention has a clean formula, is green and safe, has 0 pigments, 0 preservatives, has no side effects and has good palatability. Its preparation process is simple and reasonable, the operation is feasible, and the applicability is strong. The composition provided by the present invention can significantly reduce the levels of uric acid and xanthine oxidase, and provides broad application prospects for the preparation of uric acid-lowering products, especially foods.

[0008] The composition of the present invention contains oligofructose. On the one hand, the probiotics in the intestine can degrade the synthetic prerequisite of uric acid into purine bases that are not easily absorbed by the intestine, thereby reducing the uric acid level in the blood; and oligofructose, as a dietary fiber and prebiotic, can selectively stimulate the growth and reproduction of probiotics in the intestine, inhibit harmful bacteria, and maintain the balance of intestinal flora. For example: oligofructose can increase the value of bifidobacteria by 10 to 100 times, reduce and inhibit the production of intestinal putrefactive substances, inhibit the growth of harmful bacteria, and thus improve its uric acid-lowering effect. On the second hand, oligofructose can indirectly enhance the immune function of the human body and improve the body's resistance by regulating intestinal flora. On the third hand, severe deficiency of minerals, such as calcium, zinc, iodine, iron, etc., can cause nucleic acid metabolism disorders, increase purine production, and induce gout attacks. Oligofructose can promote the absorption of minerals such as calcium and magnesium, which is beneficial to controlling purine production.

[0009] The composition of the present invention contains resistant dextrin. On the one hand, resistant dextrin is also a dietary fiber and a prebiotic, which can be fermented and utilized by beneficial bacteria in the intestine, promote the growth and reproduction of beneficial bacteria, and regulate the balance of intestinal flora, thereby playing the role of a prebiotic. It can improve intestinal function, enhance immunity, promote the absorption of nutrients, etc. On the other hand, high fat intake will also increase free fatty acids in the body, induce the production of proinflammatory cytokines, and make urate more easily crystallized, thereby inducing acute gout. Resistant dextrin has the effect of increasing satiety and reducing appetite, which helps to control energy intake. When energy intake is controlled, it may also have a positive effect on the metabolism of fatty acids, such as prompting the body to use more fat for energy, thereby promoting the metabolic decomposition of fatty acids to a certain extent.

[0010] The composition of the present invention contains cranberry juice powder. Natural antioxidants in cranberry powder, such as vitamin C and proanthocyanidins, can effectively reduce the formation of free radicals and protect cells from oxidative damage. Proanthocyanidins are an active ingredient with multiple pharmacological effects. They have extremely strong antioxidant properties and are recognized as natural antioxidants. At the same time, they are also very strong free radical scavengers that can reduce enzyme activity and inhibit inflammation. Studies have shown that proanthocyanidins have a certain improvement effect on acute gouty arthritis in SD rats, and its mechanism may be related to inhibiting the TLR4 / NF-κB signaling pathway, thereby inhibiting inflammatory factors such as IL-1β.

[0011] The composition of the present invention contains acerola powder. Acerola powder is rich in vitamin C, which helps to enhance immunity, promote collagen synthesis, and resist oxidation. In addition, acerola powder also contains a variety of bioactive ingredients: such as flavonoids, anthocyanins, etc., which have antioxidant and anti-inflammatory effects. On the other hand, acerola powder can be used in food and beverages to increase the nutritional value and taste of the products.

[0012] To achieve the above purpose, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a composition for reducing uric acid, wherein the composition comprises, by weight: 20-35 parts of whole milk powder, 10-30 parts of prebiotics, 8-18 parts of fruit powder and 3-6 parts of composite probiotic powder; The prebiotics are composed of oligofructose and resistant dextrin; The fruit powder is composed of cranberry juice powder and acerola cherry powder; The composite probiotic powder consists of Lactobacillus plantarum TSP05, Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332 and maltodextrin, and is purchased from Jinqiao Biotechnology Co., Ltd., and the product model is PRONULIFE®UriManage.

[0013] Specifically, the weight ratio of the prebiotics to the fruit powder is 0.75-2:1.

[0014] Preferably, the weight ratio of the prebiotics to the fruit powder is 1-1.5:1.

[0015] Further preferably, the weight ratio of the prebiotics to the fruit powder is 1.1-1.2:1.

[0016] Specifically, the weight ratio of the prebiotics to the composite probiotic powder is 3-5:1.

[0017] Preferably, the weight ratio of the prebiotics to the composite probiotic powder is 3-4:1.

[0018] Further preferably, the weight ratio of the prebiotics to the composite probiotic powder is 3.5-4:1.

[0019] Specifically, the composition comprises, by weight: 20-35 parts of whole milk powder, 5-15 parts of oligofructose, 5-15 parts of resistant dextrin, 5-12 parts of cranberry juice powder, 3-6 parts of compound probiotic powder and 3-8 parts of acerola cherry powder.

[0020] Preferably, the composition comprises, by weight, 25 parts of whole milk powder, 10 parts of oligofructose, 7.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 4.5 parts of compound probiotic powder and 5 parts of acerola cherry powder.

[0021] Specifically, the bacterial count of the composite probiotic powder in the composition is ≥1.5×10 11 CFU / g.

[0022] In a second aspect, the present invention provides a method for preparing the above-mentioned composition, which comprises the following steps: mixing whole milk powder, oligofructose, resistant dextrin, cranberry juice powder, composite probiotic powder and acerola cherry powder uniformly to obtain a composition.

[0023] Specifically, the weight proportions of the whole milk powder, oligofructose, resistant dextrin, cranberry juice powder, compound probiotic powder and acerola cherry powder are: 20-35 parts of whole milk powder, 5-15 parts of oligofructose, 5-15 parts of resistant dextrin, 5-12 parts of cranberry juice powder, 3-6 parts of compound probiotic powder and 3-8 parts of acerola cherry powder.

[0024] Preferably, the weight proportions of the whole milk powder, oligofructose, resistant dextrin, cranberry juice powder, compound probiotic powder and acerola cherry powder are: 25 parts of whole milk powder, 10 parts of oligofructose, 7.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 4.5 parts of compound probiotic powder and 5 parts of acerola cherry powder.

[0025] In a third aspect, the present invention provides the use of the above-mentioned composition in the preparation of uric acid-lowering products.

[0026] Specifically, the product contains 1-5 g / dose of the composition.

[0027] Preferably, the product contains 1.2 g / dose of the composition.

[0028] Preferably, the bacterial count of the composite probiotic powder in the product is ≥1.5×10 11 CFU / g.

[0029] Specifically, the products include food, health products or medicines.

[0030] Preferably, the product is a food.

[0031] In a fourth aspect, the present invention provides a food comprising the above-mentioned composition.

[0032] Specifically, the dosage form of the food includes a liquid dosage form, a solid dosage form or a semi-solid dosage form.

[0033] Preferably, candy, soy milk, yogurt, milk, juice, canned food, biscuits, chocolate, cakes, cream, cheese, sour cream, milk powder, formula milk powder, ice cream, jam, puree, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, carbonated drinks, coffee, jelly, protein bars, energy bars, energy gel or puffed food.

[0034] Specifically, the food also includes nutritional additives that are nutritionally acceptable.

[0035] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0036] In a fifth aspect, the present invention provides a health care product, comprising the above-mentioned composition.

[0037] Specifically, the health care product also includes nutritional additives that are nutritionally acceptable.

[0038] Preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0039] Preferably, the dosage form of the health care product includes tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0040] In a sixth aspect, the present invention provides a medicine comprising the above-mentioned composition.

[0041] Specifically, the medicine also includes one or more physiologically acceptable excipients.

[0042] Preferably, the physiologically acceptable excipients include, but are not limited to, solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, adhesives, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavoring agents, sweeteners, ion exchangers, release agents, coating agents, flavoring agents or antioxidants.

[0043] Beneficial effects of the present invention: The composition provided by the present invention has a clean formula, is green and safe, contains no pigment, no preservatives, has no side effects and has good palatability. The preparation process of the composition provided by the present invention is simple and reasonable, the operation is feasible and the applicability is strong. The composition provided by the present invention can significantly reduce the level of uric acid and the level of xanthine oxidase, and provides a broad application prospect for the preparation of uric acid-lowering products, especially uric acid-lowering foods. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1.

[0045] Figure 2 These are the results of measuring xanthine oxidase levels in the liver of Examples 1-3 and Comparative Examples 1-5.

[0046] Figure 3 The following are the results of the determination of uric acid content in serum of groups 6-11 in comparative example.

[0047] Figure 4 These are the results of measuring xanthine oxidase levels in the liver of groups 6-11 in comparative examples.

[0048] Figure 5 This is the curve of changes in blood uric acid levels of volunteers. DETAILED DESCRIPTION

[0049] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0050] The materials used in the present invention are as follows: Fructooligosaccharide was purchased from Quantum Hi-Tech (Guangdong) Biological Co., Ltd., with the catalog number QHT-FOS-P95S; Resistant dextrin was purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd.; The uric acid detection kit was purchased from Solarbio, with the catalog number BC1365. The xanthine oxidase detection kit was purchased from Solarbio, with the catalog number BC1095.

[0051] The composite lactic acid bacteria powder was purchased from Jinqiao Biotechnology Co., Ltd., and the product model is PRONULIFE® UriManage. The composite lactic acid bacteria powder consists of Lactobacillus plantarum TSP05, Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332 and maltodextrin. In the composite lactic acid bacteria powder, the addition amount of Lactobacillus plantarum TSP05 is 1.05×10 11CFU / g, the addition amount of Lactobacillus fermentum TSF331 was 3×10 10 CFU / g, the addition amount of Lactobacillus reuteri TSR332 was 1.5×10 10 CFU / g, the total bacterial count in the composite lactic acid bacteria powder is 1.5×10 11 CFU / g.

[0052] Example 1 The composition of Example 1 is composed of 25 parts of whole milk powder, 10 parts of oligofructose, 7.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0053] Example 2 The composition of Example 2 is composed of 35 parts of whole milk powder, 15 parts of oligofructose, 15 parts of resistant dextrin, 12 parts of cranberry juice powder, 6 parts of composite probiotic powder and 3 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0054] Example 3 The composition of Example 3 is composed of 20 parts of whole milk powder, 5 parts of oligofructose, 5 parts of resistant dextrin, 5 parts of cranberry juice powder, 3 parts of composite probiotic powder and 8 parts of acerola powder. The above raw materials are mixed evenly to obtain a composition.

[0055] Comparative Example 1 The composition of Comparative Example 1 consists of 25 parts of whole milk powder, 10 parts of oligofructose, 10 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0056] Comparative Example 2 The composition of Comparative Example 2 is composed of 25 parts of whole milk powder, 7.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0057] Comparative Example 3 The composition of Comparative Example 3 consists of 25 parts of whole milk powder, 10 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0058] Comparative Example 4 The composition of Comparative Example 4 consists of 20 parts of whole milk powder, 20 parts of oligofructose, 7.5 parts of resistant dextrin, 5 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0059] Comparative Example 5 The composition of Comparative Example 5 consists of 25 parts of whole milk powder, 10 parts of oligofructose, 4.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 7.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0060] Comparative Example 6 The composition of Comparative Example 6 consists of 32.5 parts of whole milk powder, 10 parts of oligofructose, 7.5 parts of resistant dextrin, 5 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 2.5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0061] Comparative Example 7 The composition of Comparative Example 7 consists of 8.75 parts of whole milk powder, 15 parts of oligofructose, 11.25 parts of resistant dextrin, 15 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 2.5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0062] Comparative Example 8 The composition of Comparative Example 8 consists of 20 parts of whole milk powder, 15 parts of oligofructose, 11.25 parts of resistant dextrin, 7.25 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 4 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0063] Comparative Example 9 The composition of Comparative Example 9 consists of 42.5 parts of whole milk powder, 10 parts of cranberry juice powder, 4.5 parts of composite probiotic powder and 5 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0064] Comparative Example 10 The composition of Comparative Example 10 consists of 57.5 parts of whole milk powder and 4.5 parts of composite probiotic powder. The above raw materials are mixed uniformly to obtain a composition.

[0065] Comparative Example 11 The composition of Comparative Example 11 consists of 16.5 parts of whole milk powder, 7.5 parts of oligofructose, 7.5 parts of resistant dextrin, 15 parts of cranberry juice powder, 0.5 parts of composite probiotic powder and 15 parts of acerola powder. The above raw materials are mixed uniformly to obtain a composition.

[0066] Experimental Example 1: Constructing an animal model to verify the uric acid-lowering effects of Examples 1-3 and Comparative Examples 1-5 1. Model building and grouping A total of 50 male Kunming mice aged 6-8 weeks were randomly divided into 10 groups (5 mice in each group) after 7 days of adaptive feeding, namely, a normal group, a model group, Example 1 group to Example 3 group, and Comparative Example 1 group to Comparative Example 5 group.

[0067] During the modeling period (day 0-day 14), the normal group was gavaged with 5g / L sodium carboxymethylcellulose aqueous solution, the gavage volume was 0.1mL / 10g, and 0.05mL of normal saline was intraperitoneally injected. The model group, Example 1 group to Example 3 group, and Comparative Example 1 group to Comparative Example 5 group were gavaged with 15g / kg body weight of yeast extract, and 250mg / kg body weight of potassium oxonate was intraperitoneally injected 1 hour later.

[0068] During the intervention period (15th to 45th day), Example 1 to Example 3 and Comparative Example 1 to Comparative Example 7 were intragastrically administered with 1.2 g / kg of the composition of Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4 or Comparative Example 5, once a day. The normal group and the model group were intragastrically administered with an equal volume of physiological saline.

[0069] During the experiment, the normal group drank purified water, and the model group, Example 1 group to Example 3 group, and Comparative Example 1 group to Comparative Example 5 group all drank a yeast extract aqueous solution with a concentration of 0.5 g / L.

[0070] 2. Determination of uric acid and xanthine oxidase After the intervention, blood was collected from the mice's orbits, and the supernatant was used to determine the uric acid content in the serum. The liver was collected for the determination of xanthine oxidase levels.

[0071] The results of the determination of uric acid content in the serum of mice in Example 1-3 and Comparative Example 1-5 and the results of the determination of xanthine oxidase in the liver are shown in Figure 1-Figure 2 and Table 1. The results show that the compositions provided by Examples 1 to 3 of the present invention can significantly reduce the uric acid content in serum and the level of xanthine oxidase in the liver, and have the best effect. Examples 1 to 3 of the present invention can restore xanthine oxidase to normal levels.

[0072] Table 1 Uric acid and xanthine oxidase contents in Examples 1-3 and Comparative Examples 1-5

[0073] Experimental Example 2: Constructing an animal model to verify the uric acid-lowering effect of Comparative Examples 6-11 1. Model building and grouping A total of 40 male Kunming mice aged 6-8 weeks were randomly divided into 8 groups (5 mice in each group) after 7 days of adaptive feeding, namely, a normal group, a model group, and control group 6 to control group 11.

[0074] During the modeling period (day 0-day 14), the normal group was gavaged with 5g / L sodium carboxymethylcellulose aqueous solution, the gavage volume was 0.1mL / 10g, and 0.05mL of normal saline was injected intraperitoneally. The model group and comparative example group 6-comparative example group 11 were gavaged with 15g / kg body weight of yeast extract, and 250mg / kg body weight of potassium oxonate was injected intraperitoneally 1 hour later.

[0075] During the intervention period (15th day to 45th day), groups 6 to 11 were gavaged with 1.2 g / kg of the composition of Example 6, Example 7, Example 8, Example 9, Example 10 or Example 11, once a day. The normal group and the model group were gavaged with an equal volume of normal saline.

[0076] During the experiment, the normal group drank purified water, and the model group and control group 6 to control group 11 drank a yeast extract aqueous solution with a concentration of 0.5 g / L.

[0077] 2. Determination of uric acid and xanthine oxidase After the intervention, blood was collected from the mice's orbits, and the supernatant was used to determine the uric acid content in the serum. The liver was collected for the determination of xanthine oxidase levels.

[0078] The results of the determination of uric acid content in the serum of mice in groups 6-11 and the determination of xanthine oxidase in the liver are shown in Figure 3-Figure 4 and Table 2. The results show that Comparative Examples 6 to 11 can reduce uric acid levels and xanthine oxidase levels to varying degrees. The ratios of prebiotics, fruit powder or composite probiotic powder in Comparative Examples 6-8 and 11 are changed, resulting in poor uric acid and xanthine oxidase lowering effects. Comparative Examples 9-10 have the worst effects, which may be due to the lack of prebiotics or fruit powder.

[0079] Table 2 Uric acid and xanthine oxidase content in groups 6-13 of comparative examples

[0080] Experimental Example 3: Validation of the uric acid-lowering effects of Examples 1-3 on volunteers 40 male volunteers aged 40-50 (uric acid levels between 600-800 μmol / L) were randomly divided into 4 groups (10 people in each group), namely, no intervention group, Example 1 group-Example 3 group. The volunteers in Example 1 group-Example 3 group took the composition of Example 1, Example 2 or Example 3 respectively, and the method of taking was: 3 times a day, 1-2 hours after breakfast, lunch and dinner, with warm water below 40°C, 1.2g / time; the volunteers in the no intervention group did not receive any intervention. The intervention period was 90 days. During the intervention period, the volunteers controlled their diet and avoided taking alcohol, seafood, animal offal, meat, broth and soy products. Before the intervention and before breakfast on the 30th, 60th and 90th days after the intervention, venous blood was taken to determine the blood uric acid level. The sensory evaluation results of the volunteers in Example 1 group-Example 3 group on the compositions of Examples 1-Example 3 were collected, and the volunteers all indicated that the compositions of Examples 1-Example 3 had better taste and better palatability.

[0081] The curve of blood uric acid level changes of 40 volunteers is as follows Figure 5 As shown, the results show that the composition of Example 1 to Example 3 can effectively reduce the blood uric acid level. After 90 days of intervention, the blood uric acid level is almost restored to normal level.

[0082] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. A composition for reducing uric acid, characterized in that: The composition comprises, by weight: 20-35 parts of whole milk powder, 10-30 parts of prebiotics, 8-18 parts of fruit powder and 3-6 parts of composite probiotic powder; The prebiotics are composed of oligofructose and resistant dextrin; The fruit powder is composed of cranberry juice powder and acerola cherry powder; The composite probiotic powder is composed of Lactobacillus plantarum TSP05, Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332 and maltodextrin; The composition comprises, by weight: 20-35 parts of whole milk powder, 5-15 parts of oligofructose, 5-15 parts of resistant dextrin, 5-12 parts of cranberry juice powder, 3-6 parts of composite probiotic powder and 3-8 parts of acerola cherry powder; The weight ratio of the prebiotics to the fruit powder is 0.75-2:1; The weight ratio of the prebiotics to the composite probiotic powder is 3-5:

1.

2. The composition according to claim 1, characterized in that The composition comprises, by weight: 25 parts of whole milk powder, 10 parts of oligofructose, 7.5 parts of resistant dextrin, 10 parts of cranberry juice powder, 4.5 parts of compound probiotic powder and 5 parts of acerola cherry powder.

3. The method for preparing the composition according to any one of claims 1 to 2, characterized in that: The preparation method comprises: uniformly mixing whole milk powder, oligofructose, resistant dextrin, cranberry juice powder, composite probiotic powder and acerola cherry powder to obtain a composition.

4. Use of the composition according to any one of claims 1 to 2 in the preparation of a uric acid-lowering product.

5. The use according to claim 4, characterized in that: The product contains 1-5g of the composition, and the bacterial count specification of the composite probiotic powder in the product is ≥1.5×10 11 CFU / g.

6. A food, characterized in that The food comprises the composition according to any one of claims 1 to 2.

7. The food according to claim 6, characterized in that The dosage form of the food includes liquid dosage form, solid dosage form or semi-solid dosage form.

8. The food according to claim 6, characterized in that The food also includes nutritionally acceptable nutritional additives.

9. A medicine, characterized in that: The medicine comprises the composition according to any one of claims 1-2.

10. The drug according to claim 9, characterized in that The medicine also includes pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Composition for inhibiting hyperuricemia and application thereof

    CN113925887A

  • Probiotic composition and application thereof

    CN115252656A

Cited By

  • Uric acid reducing and gout resisting composition as well as preparation method and application thereof

    CN119405755A